Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from I-MAB ( (IMAB) ) is now available.
I-Mab announced that Wei Fu, Chairman of the Board, plans to purchase up to $2,000,000 of the company’s American Depository Shares, aligning with the company’s corporate strategy to boost shareholder value. I-Mab has prioritized givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, as its lead clinical program, with promising ongoing studies and a solid financial runway into 2027, indicating a strong focus on advancing its oncology pipeline.
More about I-MAB
I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company operates in Rockville, Maryland, and Short Hills, New Jersey.
YTD Price Performance: 7.91%
Average Trading Volume: 462,979
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $83.19M
Find detailed analytics on IMAB stock on TipRanks’ Stock Analysis page.
